Bousquet J, Akdis C A, Grattan C, Eigenmann P A, Hoffmann-Sommergruber K, Hellings P W, Agache I
MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France.
INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France.
Clin Transl Allergy. 2018 Nov 27;8:49. doi: 10.1186/s13601-018-0238-3. eCollection 2018.
The European Academy of Allergy and Clinical Immunology (EAACI) owns three journals: Allergy, Pediatric Allergy and Immunology and Clinical and Translational Allergy. One of the major goals of EAACI is to support health promotion in which prevention of allergy and asthma plays a critical role and to disseminate the knowledge of allergy to all stakeholders including the EAACI junior members. There was substantial progress in 2017 in the identification of basic mechanisms of allergic and respiratory disease and the translation of these mechanisms into clinics. Better understanding of molecular and cellular mechanisms, efforts for the development of biomarkers for disease prediction, novel prevention and intervention studies, elucidation of mechanisms of multimorbidies, entrance of new drugs in the clinics as well as recently completed phase three clinical studies and publication of a large number of allergen immunotherapy studies and metaanalyses have been the highlights of the last year.
欧洲变态反应和临床免疫学会(EAACI)拥有三本期刊:《变态反应》《儿科变态反应与免疫学》以及《临床与转化变态反应》。EAACI的主要目标之一是支持健康促进,其中预防过敏和哮喘起着关键作用,并向包括EAACI初级成员在内的所有利益相关者传播过敏知识。2017年在确定过敏性和呼吸道疾病的基本机制以及将这些机制转化为临床应用方面取得了重大进展。对分子和细胞机制的更好理解、开发疾病预测生物标志物的努力、新型预防和干预研究、多病症机制的阐明、新药进入临床以及最近完成的三期临床研究以及大量变应原免疫疗法研究和荟萃分析的发表都是去年的亮点。